E-LIB Suche - Ergebnisse für: Vyas, P.

1

Enasidenib vs conventional care in older patients with late..:

de Botton, S ; Montesinos, P ; Schuh, AC...
issn:0006-4971. , 2023

Link: http://hdl.handle.net/11..

2

A protocol for simultaneous high-sensitivity genotyping and..:

Turkalj, S ; Jakobsen, NA ; Groom, A..
doi:10.1016/j.xpro.2023.102641. , 2023

Link: https://doi.org/10.1016/..

3

An overview of targeted therapies in acute myeloid leukemia:

Turkalj, S ; Radtke, FA ; Vyas, P
doi:10.1097/hs9.0000000000000914. , 2023

Link: https://doi.org/10.1097/..

4

Fractionated vs single-dose gemtuzumab ozogamicin with dete..:

Freeman, SD ; Thomas, A ; Thomas, I...
doi:10.1182/blood.2023020630. , 2023

Link: https://doi.org/10.1182/..

5

A tubulin binding molecule drives differentiation of acute ..:

Jackson, TR ; Vuorinen, A ; Josa-Culleré, L...
doi:10.1016/j.isci.2022.104787. , 2022

Link: https://doi.org/10.1016/..

6

AML-262 Pivekimab Sunirine (PVEK, IMGN632) triplet with aza..:

Daver, N ; Montesinos, P ; Aribi, A...
doi:10.1016/S2152-2650(22)01257-5. , 2022

Link: https://doi.org/10.1016/..

7

A phase 1b study of glasdegib + azacitidine in patients wit..:

Sekeres, MA ; Schuster, M ; Joris, M...
doi:10.1007/s00277-022-04853-4. , 2022

Link: https://doi.org/10.1007/..

8

AML-399 A phase 2, open-label, multiarm, multicenter study ..:

Vyas, P ; Daver, N ; Chao, M...
doi:10.1016/S2152-2650(22)01288-5. , 2022

Link: https://doi.org/10.1016/..

9

Loss Of COP9-signalosome genes Aa 2q37 is associated with I..:

Gooding, S ; Ansari-Pour, N ; Kazeroun, MH...
doi:10.1182/blood.2022015909. , 2022

Link: https://doi.org/10.1182/..

10

Genetic and non-genetic mechanisms of inflammation may prom..:

Vyas, P
doi:10.1016/j.stem.2022.01.006. , 2022

Link: https://doi.org/10.1016/..

11

AML-432 Overall survival (OS) by IDH2 mutant allele (R140 o..:

DiNardo, CD ; de Botton, S ; Risueño, A...
doi:10.1016/S2152-2650(22)01293-9. , 2022

Link: https://doi.org/10.1016/..

12

Combined inhibition of XIAP and BCL2 drives maximal therape..:

Hashimoto, M ; Saito, Y ; Nakagawa, R...
doi:10.1038/s43018-021-00177-w. , 2022

Link: https://doi.org/10.1038/..

13

AML-464 Tolerability and efficacy of the first-in-class ant..:

Daver, N ; Vyas, P ; Kambhampati, S...
doi:10.1016/S2152-2650(22)01300-3. , 2022

Link: https://doi.org/10.1016/..

14

Shall we dance: evolving partnerships of targeted therapies..:

Perl, AE ; Vyas, P
doi:10.1158/1078-0432.ccr-22-0279. , 2022

Link: https://doi.org/10.1158/..

15

International Consensus Classification of myeloid neoplasms..:

Arber, DA ; Orazi, A ; Hasserjian, RP...
doi:10.1182/blood.2022015850. , 2022

Link: https://doi.org/10.1182/..